Syfovre and Izervay Linked to Serious Health Risks
Two new drugs, Syfovre and Izervay, were approved by the FDA in 2023 to treat age-related macular degeneration (AMD), specifically geographic atrophy related to AMD. Syfovre and Izervay are both administered as injections directly into the eye. They work by regulating the overactivated part of the immune system in your eye that causes the progression of geographic atrophy related to AMD. However, both drugs have been linked with incidents of occlusive retinal vasculitis, a severe inflammatory event of the retina’s blood vessels that often causes severe vision loss or blindness.
Schedule A Free Consultation Today!
About Syfovre and Izervay
Syfovre is manufactured by Apellis Pharmaceuticals and was approved on February 17, 2023. Upon its release to the market, it had no warning for retinal vasculitis on the label. First reports of retinal vasculitis showed up in April 2023, and the Research and Safety in Therapeutics Committee of the American Society of Retinal Specialists started immediately reporting on the issue.
Izervay is made by Astellas Pharma Inc. and launched about six months after Syfovre, receiving FDA approval on August 5, 2023. Its warning label similarly contained no warning for retinal vasculitis. Incidents of retinal vasculitis have also been seen in patients being treated with Izervay.
Syfovre and Izervay Injuries
These drugs are both injected intravitreally, meaning that the needle is inserted through the white part of the eye directly into the gel-filled interior known as the vitreous. Many different intravitreal injections have been associated with retinal vasculitis over the years. Occlusive retinal vasculitis can lead to significant vision loss if not complete blindness.
Living with age-related macular degeneration is hard enough without being additionally harmed by medication that was advertised to you or a loved one as a treatment for AMD. Cory Watson Attorneys is pursuing legal action against the manufacturers of Syfovre and Izervay due to the companies’ failure to warn patients and physicians about the serious risks of injuries and death associated with these drugs. If you or a loved experienced any of the following shortly after an injection of Syfovre or Izervay for treatment of AMD, you may be entitled to compensation:=
- Retinal vasculitis
- Retinal vascular occlusion
- Retinal artery occlusion
- A stroke of the eye
How Do I Contact an Attorney to File a Syfovre and Izervay Lawsuit?
If you took Syfovre and Izervay and have suffered an injury, you should contact a Cory Watson product liability attorney for a 100% free case consultation. Our nationwide lawyers are accepting cases from all 50 states.
About Cory Watson Attorneys
Ernest Cory, Product Liability Attorney
Cory Watson Attorneys is a nationally recognized personal injury law firm with offices in Birmingham, Alabama; Memphis, and Nashville, Tennessee. The firm has recovered more than $4 billion for clients across the country. Cory Watson attorneys are frequently at the forefront of major class actions and multidistrict litigations involving dangerous pharmaceuticals and product liability and are often appointed to leadership positions in national cases. Firm practice areas include Personal Injury, Product Liability, Class Action, Asbestos, Business & Commercial Litigation.
Birmingham Office Location
2131 Magnolia Ave s.Birmingham, AL 35205